Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Shares Outstanding (Weighted Average) (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $118.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 25.51% to $118.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $118.4 million through Dec 2025, up 25.51% year-over-year, with the annual reading at $118.4 million for FY2025, 25.51% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $118.4 million in Q4 2025 for NewAmsterdam Pharma, roughly flat from $119.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $119.0 million in Q3 2025 to a low of $19.4 million in Q4 2022.
  • Historically, Shares Outstanding (Weighted Average) has averaged $91.6 million across 4 years, with a median of $94.4 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): skyrocketed 324.6% in 2023 and later increased 8.26% in 2024.
  • Year by year, Shares Outstanding (Weighted Average) stood at $19.4 million in 2022, then surged by 324.6% to $82.2 million in 2023, then increased by 14.84% to $94.4 million in 2024, then increased by 25.51% to $118.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for NAMS at $118.4 million in Q4 2025, $119.0 million in Q3 2025, and $117.3 million in Q2 2025.